In vivo Microbiology

 

With the rising prevalence of drug-resistant microorganisms, effective and potent antimicrobial agents are becoming increasingly more relevant in order to treat infectious diseases.  The scientific team at Pharmacology Discovery Services works diligently with our clients to provide a robust portfolio of in vivo antimicrobial models at our BSL-2 facility to support the discovery and development of novel therapies. 

Our team of Technical and Study Directors have experience in antimicrobial drug development and clinical microbiology.  We can meet a variety of study endpoints to generate the high-quality, reproducible data your projects require including minimal data scatter and dose-response to standard antimicrobial agents.  Our models have been used to test small molecules, drug combinations, biologics, RNAi, liposomal formulations, nanoparticles, and vaccines.  To meet the needs of your specific antimicrobial drug discovery project we also have the flexibility and expertise to develop custom in vivo models.


Speak with
an expert

Download our
model list

ESCMID/ASM
2018 Poster

 

 


Determine In Vivo Efficacy with Survival and Tissue Burden Models

We have over 70 validated infection models with clinically relevant pathogens:

  • Ocular, peritonitis, pneumonia or sepsis
  • Skin, thigh muscle, wound or vaginal
  • Models with multi-drug resistant (MDR) bacterial pathogens

Pathogen types include:

  • Fungi: C. albicans, A. fumigatus
  • Gram-negative bacteria: A. baumannii, E. coli, K. pneumoniae, N. gonorrhoeae, P. aeruginosa
  • Gram-positive bacteria: E. faecalis, S. aureus, S. epidermidis, S. pneumoniae, S. pyogenes

Flexible Dosing Routes:

  • ID, IM, IN, IP, IT, IV, PO, RO, SC, topical or vaginal
  • Continuous IV infusion or dose fractionation

Multiple Readouts Available

  • Survival or microbial counts
  • Counts of resistant microbial variants
  • Histopathology
  • PK exposure
  • Cytokine profile
  • Flow cytometry
  • quantitative RT-PCR

In Vivo Pharmacology Expertise

Each of our Technical Directors specializes in selected therapeutic areas so they may provide expert scientific support to our clients.  This involves consulting with clients to identify an appropriate model to meet their scientific objectives, designing studies and writing the custom protocols and statements of work (SOWs) to meet quality assurance guidelines.  They also work closely with our Study Directors to assure that SOWs are clear and that all methods and timelines are feasible.  Our laboratory staff also averages 15 years of experience conducting in vivo pharmacology studies.

Publications

Antimicrobial In Vivo Models
Model Name Item Number Species Price/Animal ($USD)
Aspergillus fumigatus (ATCC 13073), Systemic (IV) Infection, LD90-100 609100 Mouse 200
Candida albicans (ATCC 10231), Systemic (IV) Infection, LD90-100 609010 Mouse 180
Candida albicans (ATCC 44858), Systemic (IV) Infection, LD90-100 609020 Mouse 180
Candida albicans (ATCC 44858), Vulvovaginal Candidiasis 609050 Rat 450
Candida albicans (R303), Systemic (IV) Infection, Kidney, CFU/g 609035 Mouse 260
Candida albicans, Azole resistant (R357), Systemic Infection, Kidney, CFU/g 609040 Mouse 260
Candida albicans, Azole resistant (R357),Vulvovaginal Infection 609060 Rat 450
Acinetobacter baumannii (ATCC 17978), Lung Infection Model, CFU/g 608800 Mouse 260
Acinetobacter baumannii ADC-25 OXA-23 OXA-66 (FDA-CDC AR-BANK#0282), Lung Infection Model 608820 Mouse 260
Escherichia coli (ATCC 25922), Peritonitis, LD90-100 608310 Mouse 155
Escherichia coli (ATCC 25922),Thigh Infection Model, CFU/g 608330 Mouse 260
Escherichia coli (ATCC 700336), Urinary Tract Infection Model, 7 day 608380 Mouse 400
Escherichia coli MCR-1 ESBL (FDA-CDC AR-BANK#0349), Thigh Infection Model, CFU/g 608335 Mouse 260
Escherichia coli NDM-1 (FDA-CDC AR-BANK#0055),Thigh Infection Model, CFU/g 608340 Mouse 260
Klebsiella pneumoniae (ATCC 10031), Peritonitis, LD90-100 608510 Mouse 155
Klebsiella pneumoniae (ATCC 43816), Lung Infection Model, CFU/g 608550 Mouse 260
Klebsiella pneumoniae (ATCC 43816), Peritonitis, LD90-100 608540 Mouse 155
Klebsiella pneumoniae (ATCC 43816), Thigh Infection Model, CFU/g 608570 Mouse 260
Klebsiella pneumoniae (ATCC 43816), Thigh Infection Model, CFU/g 608575 Rat 360
Klebsiella pneumoniae, Carbapenem resistant KPC-2 (BAA-1705), Lung Infection Model, CFU/g 608572 Mouse 250
Klebsiella pneumoniae KPC-2, (BAA-1705), Thigh Infection Model, CFU/g 608571 Mouse 260
Klebsiella pneumoniae NDM-1, (NCTC-13443), Thigh Infection Model, CFU/g 608573 Mouse 260
Klebsiella pneumoniae NDM-1, (NCTC-13443), Lung Infection Model, CFU/g 608574 Mouse 250
Neisseria gonorrhoeae (FA1090 ATCC 700825), Vaginal Infection Model 608600 Mouse 360
Pseudomonas aeruginosa (ATCC 15692), Ocular Infection Model, CFU/g 608690 Mouse 260
Pseudomonas aeruginosa (ATCC 27853), Lung Infection Model, CFU/g 608640 Mouse 260
Pseudomonas aeruginosa (ATCC 27853), Peritonitis, LD90-100 608620 Mouse 155
Pseudomonas aeruginosa (ATCC 27853), Thigh Infection Model, CFU/g 608650 Mouse 260
Pseudomonas aeruginosa (ATCC 9027), Peritonitis, LD90-100 608610 Mouse 155
Pseudomonas aeruginosa Carbapenem Resistant (FDA-CDC AR-BANK#0094), Lung Infection Model, CFU/g 608643 Mouse 260
Pseudomonas aeruginosa Carbapenem Resistant (FDA-CDC AR-BANK#0094), Thigh Infection Model, CFU/g 608653 Mouse 260
Pseudomonas aeruginosa Carbapenem Resistant (FDA-CDC AR-BANK#0264), Lung Infection Model, CFU/g 608649 Mouse 260
Pseudomonas aeruginosa Carbapenem Resistant (FDA-CDC AR-BANK#0264), Thigh Infection Model, CFU/g 608659 Mouse 260
Pseudomonas aeruginosa Carbepenem Resistant (LES 431), Lung Infection Model, CFU/g 608645 Mouse 260
Pseudomonas aeruginosa Carbepenem Resistant (LES 431), Peritonitis, LD90-100 608630 Mouse 155
Pseudomonas aeruginosa Carbepenem Resistant (LES 431), Thigh Infection Model, CFU/g 608655 Mouse 255
Pseudomonas aeruginosa IMP-1 (FDA-CDC AR-BANK#0103), Lung Infection Model, CFU/g 608644 Mouse 260
Pseudomonas aeruginosa IMP-1 (FDA-CDC AR-BANK#0103), Thigh Infection Model, CFU/g 608654 Mouse 260
Pseudomonas aeruginosa OXA-2 OXA-50 (FDA-CDC AR-BANK#0105), Lung Infection Model, CFU/g 608646 Mouse 260
Pseudomonas aeruginosa OXA-2 OXA-50 (FDA-CDC AR-BANK#0105), Thigh Infection Model, CFU/g 608656 Mouse 260
Pseudomonas aeruginosa SPM-1 (FDA-CDC AR-BANK#0064), Lung Infection Model, CFU/g 608642 Mouse 260
Pseudomonas aeruginosa SPM-1 (FDA-CDC AR-BANK#0064), Thigh Infection Model, CFU/g 608652 Mouse 260
Pseudomonas aeruginosa VIM-2 (FDA-CDC AR-BANK#0108), Lung Infection Model, CFU/g 608647 Mouse 260
Pseudomonas aeruginosa VIM-2 (FDA-CDC AR-BANK#0108), Thigh Infection Model, CFU/g 608657 Mouse 260
Pseudomonas aeruginosa VIM-4 (FDA-CDC AR-BANK#0054), Lung Infection Model, CFU/g 608641 Mouse 260
Pseudomonas aeruginosa VIM-4 (FDA-CDC AR-BANK#0054), Thigh Infection Model, CFU/g 608651 Mouse 260
Enterococcus faecalis (ATCC 29212), Peritonitis, LD90-100 608220 Mouse 155
Enterococcus faecalis VRE (ATCC 51575), Peritonitis, LD90-100 608250 Mouse 155
Enterococcus faecalis VRE (ATCC 51575), Systemic (IV), Kidney CFU/g 608270 Mouse 260
Staphylococcus aureus (ATCC 29213), Thigh Infection Model, CFU/g 608105 Mouse 260
Staphylococcus aureus (Smith, ATCC 19636), Peritonitis, LD90-100 608010 Mouse 155
Staphylococcus aureus (Smith, ATCC 19636), Thigh Infection Model CFU/g 608050 Mouse 260
Staphylococcus aureus (Smith, ATCC 19636),Dermal Infection 608070 Mouse 260
Staphylococcus aureus MRSA (ATCC 33591), Lung Infection Model, CFU/g 608125 Mouse 260
Staphylococcus aureus MRSA (ATCC 33591), Peritonitis, LD90-100 608110 Mouse 155
Staphylococcus aureus MRSA (ATCC 33591), Thigh Infection Model, CFU/g 608130 Mouse 260
Staphylococcus aureus MRSA (ATCC 33592), Peritonitis, LD90-100 608140 Mouse 155
Staphylococcus aureus USA300 MRSA (BAA-1556), Dermal Infection  608207 Mouse 270
Staphylococcus aureus USA300 MRSA (BAA-1556), Peritonitis, LD90-100 608206 Mouse 155
Staphylococcus aureus USA300 MRSA (BAA-1556), Thigh Infection CFU/g 608208 Mouse 260
Staphylococcus aureus USA300 MRSA (BAA-1717), Dermal Infection  608190 Mouse 270
Staphylococcus aureus USA300 MRSA (BAA-1717), Disseminated Infection, LD90-100 608188 Mouse 165
Staphylococcus aureus USA300 MRSA (BAA-1717), Wound Infection, CFU/g 608200 Mouse 320
Staphylococcus aureus VRSA (VRS-2), Thigh Infection Model, CFU/g 608180 Mouse 260
Staphylococcus epidermidis (ATCC 12228), Peritonitis, LD90-100 608150 Mouse 155
Streptococcus pneumoniae (ATCC 6301), Lung Infection Model, LD90-100 608100 Mouse 175
Streptococcus pneumoniae (ATCC 6303), Lung Infection Model, CFU/g 608095 Mouse 250
Streptococcus pneumoniae (ATCC 6301), Peritonitis, LD90-100 608080 Mouse 155
Streptococcus pyogenes (ATCC 14289), Peritonitis, LD90-100 608700 Mouse 155
Septic Shock, Cecal Ligation and Puncture 576680 Mouse 370
Septic Shock, Lipopolysaccharide 576700 Mouse 200
Septic Shock, Lipopolysaccharide (without galactosamine) 576710 Mouse 200
Septic Shock, Lipopolysaccharide 576750 Rat 270